Trial
NCT03055195
Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
GlaxoSmithKline
Collaborators
—
Condition
Dermatitis, Atopic
Intervention
Mepolizumab 100 mg
Why stopped
Study reached pre-determined futility criteria following interim analysis. No safety concerns were noted.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-02-25